Navigation Links
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Date:12/8/2008

SEATTLE, Dec. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that the results of three Italian multicenter studies utilizing Zevalin(R) ([90Y]-ibritumomab tiuxetan) were presented at the American Society of Hematology (ASH) 50th Annual Meeting in San Francisco, CA.

In one presentation, the Italian Cooperative Study Group in a phase II study investigated the use of single dose Zevalin as sole initial treatment in 15 patients with advanced stage (III-IV) follicular NHL. Ninety-three percent (93%) of patients had a response with 73% achieving a complete remission (CR). At a median follow-up of 10 months, 93% of patients are alive, with 71% in continuous CR. No patients required hematopoietic growth factors. Hematologic toxicity was low and quickly reversible; 7 patients developed grade 3 thrombocytopenia and 5 required platelet transfusions.

In a second presentation, investigators from the European Institute of Oncology, Milan treated 13 patients with relapsed or refractory primary gastric NHL including 9 patients with Mucosa Associated Lymphoid Tissue or MALT with a single dose of Zevalin. Ten of 13 patients achieved a CR with all 9 patients (100%) with MALT achieving a CR. Toxicities were mainly hematologic and reversible. After a median follow up of 36 months 9 of 10 CR's (90%) are disease free.

The potential benefits of RIT with Zevalin combined with BEAM conditioning regimen (Z-BEAM) followed by autologous stem cell transplantation (ASCT) for patients who fail to achieve a CR after front line rituximab containing multi- agent chemotherapy for advanced NHL was also presented. The results of the Italian Multicenter Study demonstrated that among 53 patients who failed to achieve CR after CHOP-R, the Z-BEAM followed by ASCT resulted in a 74% CR rate. At a median follow up of 175 days post transplant 40 patients (75%) are alive, 30 patients (57%) in CR. Four
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products
2. Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
3. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
4. Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations
5. La Rabida Children's Hospital to Host Three-Day Course on Gait Treatment Options for Children with Cerebral Palsy
6. Three Chef-Dietitians Win CanolaInfo Recipe Contest
7. Three Chicago Area Fertility Agencies Launch Shared Risk Program
8. Innerscope Research Strengthens Management Team With Three Executive Appointments
9. Three-Quarters of Americans and Industry Leaders Want Health Care Reform in President-elect Obamas First Term
10. New Jersey Jury Awards $12.9 Million to Three Patients Whose Use of Roche Acne Medication Accutane Found to Cause Severe Bowel Illness
11. Three Community Leaders to Receive Foundations 2008 California Peace Prize

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009).... 6 Those biopharmaceutical compan...exible elements into their business models will be...maintain attractive long-term returns, according t...e Royalty Partners, a global healthcare private eq...re strategy firm. ,, The paper, "Maintaining At...
(Date:11/6/2009)...ulletproof Blog , the nation,s premier high-stake...y with former Speaker of the U.S. House of Represe...nd regulatory developments to effect America,s bus...ingrich provides insights on the most significant ...vernment, including healthcare reform and the newl...
(Date:11/6/2009)...ire-FirstCall/ -- Allied World Assurance,Company H...lied World U.S.,Nicole Baummer, Assistant Vice Pr...tal Claims and Marjorie Thompson, Vice President, ...s year,s Professional Liability Underwriting,Socie...Chicago, Illinois,November 11-13, 2009. , ...
(Date:11/6/2009)...k for Health, an alliance of Washington state busi...today released the results of a first-of-its-kind ...ashington,s life sciences sector has passed many o...ch the state,s economy was founded, and is in the ...ology-based industries of the state. ,, Specia...
(Date:11/6/2009)... current health care debate in the United States i...ditures, lifestyle choices and life expectancy hav...The U.S. spends on average more than $45,000 per y...e Europeans spend $12,000 for the same age group. ...f dying than Europeans in the next year. But, more...
Breaking Medicine News(10 mins):Health News:Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top 2Health News:Former House Speaker Newt Gingrich Shares Insights on Healthcare Reform and the Federal Pay Czar with BulletproofBlog.com 2Health News:Allied World's Nicole Baummer and Marjorie Thompson to Speak at PLUS International Conference 2Health News:Allied World's Nicole Baummer and Marjorie Thompson to Speak at PLUS International Conference 3Health News:New Study: Life Science Jobs Total 77,000 in Washington State 2Health News:New Study: Life Science Jobs Total 77,000 in Washington State 3Health News:Carnegie Mellon Researcher Links Health Care Debate to Risk of Dying in the U.S. and Europe 2Health News:Carnegie Mellon Researcher Links Health Care Debate to Risk of Dying in the U.S. and Europe 3Health News:Carnegie Mellon Researcher Links Health Care Debate to Risk of Dying in the U.S. and Europe 4
... According to a Norwegian study of 1656 subjects o...dust and fumes in the workplace is linked to a sig...ally, 2500 subjects from the city of Bergen and it...ears 1656 of the original participants were revisi...
... A new hope for patients with type 2 diabetes. Acc...tients with type 2 diabetes have been selected for... factor for type 2 diabetes. In type 1 diabetes, t...iddle age. Pancreas transplantation, giving ...
... Radiotherapy and chemotherapy simultaneously aid ...e box. Treatment for laryngeal cancer often includ...nt has to learn to speak through an opening made i...of Dallas have been looking into other treatment a...
... It is a slow killer that ticks away in one out of...onds. These were among the facts and figures trott... on World Heart Day. Gathered in front of the Vict...port Corporation (BMTC). The Commissioner of...
... With man's insatiable quest for urbanization or m...creasing day by day.It is high time they pay atten...ul life style.//This article is an eye-opener for ...o cause life threatning cardiac arrest in patients...
... According to a recent study in Texas there's a fi...erous lesions on the cervix. Previous research has...PV)// may increase the risk of cervical cancer. ... and another two years later. Those who were free ...
Other Medicine News:
(Date:11/5/2009)... Nov. 5 Helix BioPharma ...oday that its Phase II trial of Topical Interferon...AGW) has completed patient enrollment, with the re.... ,, The double-blind and placebo-controlled Ph...rmany and Sweden. Patients participating in the t...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- Air Methods Corporation (...nded September 30, 2009. Revenue increased 3% to ... quarter. For the nine-month period, revenue incr... in the prior-year nine-month period. The prior-y...llion in revenue generated from hurricane response...
(Date:11/5/2009)... Trubion Pharmaceuticals,...esults for its third quarter and nine months ended...com/cgi-bin/prnh/20090320/TRUBIONLOGO ) ,, Thi... ,, Revenue for the third quarter and nine mon....8 million, respectively, compared with $3.8 milli...
Breaking Medicine Technology:Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 3Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 5Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 6Air Methods Reports 3Q2009 Results and 4Q2009 Update 2Air Methods Reports 3Q2009 Results and 4Q2009 Update 3Air Methods Reports 3Q2009 Results and 4Q2009 Update 4Air Methods Reports 3Q2009 Results and 4Q2009 Update 5Air Methods Reports 3Q2009 Results and 4Q2009 Update 6Air Methods Reports 3Q2009 Results and 4Q2009 Update 7Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 2Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 3Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 4Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 5Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 6Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 7Inverness Medical Innovations Schedules Conference Call for 10 3A00 a m ET October 27 2009 to Discuss Third Quarter 2009 Results 14544 1Inverness Medical Innovations Schedules Conference Call for 10 3A00 a m ET October 27 2009 to Discuss Third Quarter 2009 Results 14544 2Hologic to Present at Citis 2009 Sixth Annual Small Mid Cap Conference 5609 1B Braun and Amerinet Sign to Expand Infusion Therapy Offerings 5606 1B Braun and Amerinet Sign to Expand Infusion Therapy Offerings 5606 2B Braun and Amerinet Sign to Expand Infusion Therapy Offerings 5606 3
...ire-FirstCall/ - Predictive medicine company PreMD... has entered into a fully funded collaborative cli...ic companies. PreMD,s PREVU* skin cholesterol test...tic company,s skin care products in a European cli...udy completed by PreMD with the cosmetic company. ...
...er 24 IPSOGEN SA,(Marseille, France and New Haven...ar diagnostic assays for leukemia and breast cance...Dx(TM) HER2 test. Developped on the MapQuant,Dx(TM...HER2 accurately,measures a set of HER2-amplified g...This new HER2 test provides reliable, intelligible...
Other Medicine Technology:PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate 2Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer 2Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer 3
...ce intended for highly accurate measurements of in...ost important metric for the diagnosis and treatme..., randomized, five-year National Institute of Heal... central cornea thickness (CCT) is an important an...
Gonochek - II Tubes
...y rapid test designed specifically for detecting g...one device. Fecal occult blood tests do not provi...ns. This CLIA Waived test aids in the diagnosis a...may be encountered in intensive care areas, emerge...
...s the only procedure designed for patients with a ... presbyopic patients who would benefit from a sphe...hieve a myopic endpoint of between -1.00 D and -2....ove near vision. CK is unique in that it uses rad...
Medicine Products: